CordenPharma has signed a strategic partnership with Viking Therapeutics for the development and manufacturing of VK2735, a GLP-1 drug candidate
This selection may also have influenced the observed adverse event rates, as treatment tolerability and physician familiarity with specific agents may have varied over time, potentially affecting both reporting and management of side effects
doi: 10.1159/000506879CrossRefGoogle ScholarPubMed Chanson, P., Arnoux, A., Mavromati, M., Brailly-Tabard, S., Massart, C., Young, & J., for the VARIETE Investigators (2016)
Plan for side effects: If you feel unwell, would you rather be at home in bed or is it manageable during your workday
Some preclinical comparative studies have suggested that GHK-Cu performs comparably to 5% minoxidil in stimulating hair follicle growth in organ culture, though through a different mechanism minoxidil opens potassium channels and increases blood flow, while GHK-Cu acts on growth factor signaling and matrix remodeling